Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Williams, Justin P ^a   Kim, Inki ^b   Ito, Emma ^a   Shi, Wei ^a   Yue, Shijun ^a   Siu, Lillian L ^a   Waldron, John ^c   O'Sullivan, Brian ^c   Yip, Kenneth W ^a   Liu, Fei Fei ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Asan Medical Center   (South Korea)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; DRUG SCREENING; HEAD AND NECK NEOPLASMS; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; QUINAZOLINONES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84901322057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098557     Document Type: Article

References (56)

1. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
2. Shin DM, Khuri FR (2013) Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 35: 443-453.
3. Strojan P, Corry J, Eisbruch A, Vermorken JB, Mendenhall WM, et al. (2013) Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate. Head Neck.
4. Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672. (Pubitemid 46622088)
5. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, et al. (2004) SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64: 6166-6173. (Pubitemid 39129418)
6. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, et al. (2005) Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36: 1127-1134. (Pubitemid 41443266)
7. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, et al. (2004) Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 17: 895-904. (Pubitemid 38993773)
8. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, et al. (2007) Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31: 1458-1468. (Pubitemid 46945355)
9. Martin V, Botta F, Zanellato E, Molinari F, Crippa S, et al. (2012) Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol 27: 785-792.
10. Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584. (Pubitemid 23229640)
11. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, et al. (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-4176. (Pubitemid 46622295)
12. Egloff AM, Grandis JR (2008) Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol 35: 286-297. (Pubitemid 351787698)
13. Ford AC, Grandis JR (2003) Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25: 67-73. (Pubitemid 36005333)
14. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578. (Pubitemid 43209104)
15. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7: 493-507.
16. Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, et al. (2008) Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 7: 1880-1889.
17. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, et al. (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924-11932.
18. Nam HJ, Ching KA, Kan J, Kim HP, Han SW, et al. (2012) Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther 11: 439-451.
19. Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, et al. (2013) Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One 8: e56112.
20. Clinicaltrials.gov Complete list of Clinical Trials involving Dacomitinib (PF- 00299804) Available at: http://wwwclinicaltrialsgov/ct2/results?term=PF- 00299804&pg= 1. pp. Accessed 2012 Dec 15.
21. Ou SH (2012) Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 83: 407-421.
22. Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, et al. (2011) Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17: 1131-1139.
23. Haikonen J, Rantanen V, Pekkola K, Kulmala J, Grenman R (2003) Does skin fibroblast radiosensitivity predict squamous cancer cell radiosensitivity of the same individual? Int J Cancer 103: 784-788. (Pubitemid 36110236)
24. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
25. Hui AB, Yue S, Shi W, Alajez NM, Ito E, et al. (2009) Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res 15: 3716-3724.
26. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, et al. (2005) Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11: 8131-8144. (Pubitemid 41698758)
27. Kato H, Ito E, Shi W, Alajez NM, Yue S, et al. (2010) Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res 16: 898-911.
28. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, et al. (2009) Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27: 6213-6221.
29. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
30. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, et al. (2002) Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 885-892. (Pubitemid 34742122)
31. Tejani MA, Cohen RB, Mehra R (2010) The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics 4: 173-185.
32. Fury MG, Pfister DG (2011) Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw 9: 681-689.
33. Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59: 21-26.
34. Quesnelle KM, Boehm AL, Grandis JR (2007) STAT-mediated EGFR signaling in cancer. J Cell Biochem 102: 311-319. (Pubitemid 47519405)
35. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, et al. (2003) Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63: 2948-2956. (Pubitemid 36667168)
36. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, et al. (2008) Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 73: 1632-1642. (Pubitemid 351724352)
37. Zimmermann M, Zouhair A, Azria D, Ozsahin M (2006) The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 1: 11.
38. Feng FY, Lopez CA, Normolle DP, Varambally S, Li X, et al. (2007) Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 13: 2512-2518. (Pubitemid 46698604)
39. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, et al. (2003) EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 55: 713-723. (Pubitemid 36172491)
40. Shintani S, Kiyota A, Mihara M, Sumida T, Kayahara H, et al. (2003) Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Am J Clin Oncol 26: e150-156.
41. Harari PM, Huang SM (2004) Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 58: 976-983. (Pubitemid 38221159)
42. Chen DJ, Nirodi CS (2007) The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 13: 6555-6560. (Pubitemid 350206788)
43. Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, et al. (2009) Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 4: e6539.
44. Pawlik TM, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942. (Pubitemid 38834285)
45. Thariat J, Yildirim G, Mason KA, Garden AS, Milas L, et al. (2007) Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol 12: 99-110. (Pubitemid 46632467)
46. Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72: 257-266. (Pubitemid 39265378)
47. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27: 3944-3956. (Pubitemid 351913636)
48. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, et al. (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3: 99ra86.
49. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, et al. (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-6837.
50. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075. (Pubitemid 351439466)
51. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, et al. (2006) Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42: 109- 111.
52. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, et al. (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12: 5064-5073. (Pubitemid 44453332)
53. Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, et al. (2011) The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol 3: 11.
54. Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, et al. (2010) Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 29: 5135-5145.
55. Hui AB, Lin A, Xu W, Waldron L, Perez-Ordonez B, et al. (2013) Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res 19: 2154-2162.
56. Pogorzelski M, Ting S, Gauler TC, Breitenbuecher F, Vossebein I, et al. (2014) Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. Cell Death Dis 5: e1091.